Coronavirus / COVID

MediFind's Patrick Howie examines the consolidation of resources during pandemics amid concerns that funding will not return to other areas of health research.

A look into the long-term implications of the virus on athletes' cardiovascular fitness.

What we've seen non-immunized communities do for previously eradicated outbreaks.

Eli Lilly’s investigational therapy, LY-CoV555, was shown to be well-tolerated and met its primary endpoint for one of its doses.

The logistics of supplying the vaccine are being handled by a collaboration of federal agencies. The DoD, parts of HHS, and CDC are coordinating supply, production, and distribution.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.

A survey from The Ohio State University shows a majority of Americans would get an approved vaccine.

COVID-19 patients require supervised pulmonary rehabilitation to recover ERS researchers say.

Lockdowns implemented for pandemic control have broad health, social, and economic consequences. This is especially true for people who live and work in slum communities around the world.

University of Maryland professor of medical technology answers where limited testing resources ought to be directed given pandemic supply issues.

Though it may be associated with the past in popular culture, tuberculosis is still the world’s most fatal infectious disease, killing an estimated 1.5 million people each year.

In a newly published paper, investigators believe the novel virus will follow similar patterns to seasonal viruses like influenza.

National Academies committee releases discussion draft on equitable allocation of vaccine against novel coronavirus for public comment.

New ACTT-2 findings show notable promise for a combination of the rheumatoid arthritis drug and the EUA-approved antiviral therapy.

Delayed or avoided medical care can increase death, severity of illness, and the chronic health impacts of acute illness.

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

University of Maryland professor of medical technology explains the ways speed and accuracy are weighed when testing is deployed to detect COVID-19.

An examination of ventilator patients found a significant number of them could suffer from a variety of life-long injuries.

COVID-19 is a threat to everyone without immunity, but obese patients fare worse on average.

Review and meta-analysis identifies clinical manifestations, risk factors, and maternal and perinatal outcomes associated with COVID-19 in pregnancy.

A discussion with an Ohio State investigator on early CMR findings among young athletes.

Investigators resumed phase 3 international assessments after independent committees and regulators deemed it safe to do so.

In another of many hand sanitizer recalls since the start of the pandemic, FDA is working with Medek LLC to remove all lots of “M” hand sanitizer from store shelves.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.